key: cord-0938506-9g6tw1za
authors: Greenhawt, Matthew; Abrams, Elissa M.; Shaker, Marcus; Chu, Derek K.; Kahn, David; Akin, Cem; Alqurashi, Waleed; Arkwright, Peter; Baldwin, James L.; Ben-Shoshan, Moshe; Bernstein, Jonathan; Bingeman, Theresa; Blumchen, Katerina; Byrne, Aideen; Bognanni, Antonio; Campbell, Dianne; Campbell, Ronna; Chagla, Zain; Chan, Edmond S.; Chan, Jeffrey; Comberiatti, Pasquale; Dribin, Timothy E.; Ellis, Anne K.; Fleischer, David M.; Fox, Adam; Frischmeyer-Guerrerio, Pamela A.; Gagnon, Remi; Grayson, Mitchell H.; Horner, Caroline C.; Hourihane, Johnathan; Katelaris, Constance H.; Kim, Harold; Kelso, John M.; Lang, David; Ledford, Dennis; Levin, Michael; Lieberman, Jay; Loh, Richard; Mack, Doug; Mazer, Bruce; Mosnaim, Gissele; Munblit, Daniel; Mustafa, S Shahzad; Nanda, Anil; Oppenheimer, John; Perrett, Kirsten P.; Ramsey, Allison; Rank, Matt; Robertson, Kara; Shiek, Javed; Spergel, Jonathan M.; Stukus, David; Tang, Mimi LK.; Tracy, James M.; Turner, Paul J.; Whalen-Browne, Anna; Wallace, Dana; Wang, Julie; Wasserman, Susan; Witty, John K.; Worm, Margitta; Vander Leek, Timothy K.; Golden, David BK.
title: The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach
date: 2021-06-18
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.06.006
sha: 8d2baeab95339c04b48d63985dd9d041ffb5eee4
doc_id: 938506
cord_uid: 9g6tw1za

Concerns for anaphylaxis may hamper SARS-CoV-2 immunization efforts. We convened a multi-disciplinary group of international experts in anaphylaxis comprised of allergy, infectious disease, emergency medicine, and front-line clinicians to systematically develop recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions. Medline, EMBASE, Web of Science, the WHO global coronavirus database, and the grey literature (inception-March 19, 2021) were systematically searched. Paired reviewers independently selected studies addressing anaphylaxis after SARS-CoV-2 vaccination, polyethylene glycol (PEG) and polysorbate allergy, and accuracy of allergy testing for SARS-CoV-2 vaccine allergy. Random effects models synthesized the data to inform recommendations based on the GRADE approach, agreed upon using a modified Delphi panel. The incidence of SARS-CoV-2 vaccine anaphylaxis is 7.91 cases/million (n=41,000,000 vaccinations, 95%CI 4.02-15.59; 26 studies, moderate certainty), the prevalence of PEG allergy is 103 cases/million (95%CI 88-120; 2 studies, very low certainty), and the sensitivity for PEG skin testing is poor though specificity is high (15 studies, very low certainty). We recommend vaccination over either no vaccination or performing SARS-CoV-2 vaccine/excipient screening allergy testing for individuals without history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient, and a shared decision-making paradigm in consultation with an allergy specialist for individuals with a history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient. We recommend further research to clarify SARS-CoV-2 vaccine/vaccine excipient testing utility in individuals potentially allergic to SARS-CoV2 vaccines or their excipients.

Abstract: Concerns for anaphylaxis may hamper SARS-CoV-2 immunization efforts. We 432 convened a multi-disciplinary group of international experts in anaphylaxis comprised of allergy, 433 infectious disease, emergency medicine, and front-line clinicians to systematically develop 434 recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions. Medline, 435 EMBASE, Web of Science, the WHO global coronavirus database, and the grey literature 436 (inception-March 19, 2021) were systematically searched. Paired reviewers independently 437 selected studies addressing anaphylaxis after SARS-CoV-2 vaccination, polyethylene glycol 438 (PEG) and polysorbate allergy, and accuracy of allergy testing for SARS-CoV-2 vaccine allergy. 439

Random effects models synthesized the data to inform recommendations based on the GRADE 440 approach, agreed upon using a modified Delphi panel. The incidence of SARS-CoV-2 vaccine 441 anaphylaxis is 7.91 cases/million (n=41,000,000 vaccinations, 26 studies, 442 moderate certainty), the prevalence of PEG allergy is 103 cases/million (95%CI 88-120; 2 443 studies, very low certainty), and the sensitivity for PEG skin testing is poor though specificity is 444 high (15 studies, very low certainty). We recommend vaccination over either no vaccination or 445

performing SARS-CoV-2 vaccine/excipient screening allergy testing for individuals without 446 history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient, and a shared 447 decision-making paradigm in consultation with an allergy specialist for individuals with a history 448 of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient. We recommend further 449 research to clarify SARS-CoV-2 vaccine/vaccine excipient testing utility in individuals 450 potentially allergic to SARS-CoV2 vaccines or their excipients. 451 452

Funding: none 453 454 symptoms within 3 days of vaccination. 28 These reports all indicate that anaphylactic reactions to 501 the SARS-CoV-2 mRNA vaccines may occur but are rare. 502 503

Reports of severe allergic reactions, including anaphylaxis, have prompted concern that the new 504 mRNA vaccine platform has the potential to cause allergic reactions (including anaphylaxis) at a 505 greater rate than other vaccines. A lesser degree of concern is shared for adenovirus vector 506

vaccines as there is more experience with this platform. These concerns likely contribute to 507 vaccine hesitancy and must be weighed against the life-saving and disease-mitigating benefits of 508 SARS-CoV-2 vaccination. Given the lack of an established international evidence-based 509 approach to reactions attributable to these vaccines, this group of international experts in the 510 diagnosis and management of anaphylaxis has organized an evidence-based, consensus guidance 511

for the diagnosis and management of severe allergic reactions, including anaphylaxis, to SARS-512

CoV-2 vaccines. 513 514

Methods: 515

An ad hoc panel of clinical experts from the US, Canada, UK, Europe (Ireland, Germany, Italy), 516

South Africa, and Australia came together to synthesize the current evidence regarding severe 517 allergic reactions to the SARS-CoV-2 vaccines, and provide consensus recommendations 518 regarding the epidemiology, risk factors, assessment, and management of patients at possible risk 519

for a severe allergic reaction to a SARS-CoV-2 vaccine from a societal perspective. The panel 520

was chosen based on expertise in anaphylaxis diagnosis, management, and policy. The group 521

included representation of Infectious Disease clinicians, clinicians serving as front-line 522 vaccinators, and allergy specialists with prior expertise in policy related to adverse reactions to 523 vaccines for infectious diseases. Direct financial and industry-related conflicts of interest (e.g., 524

direct or indirect involvement with the development or clinical trials related to SARS-CoV-2 525 vaccines) were not permitted and were considered disqualifying. Work unrelated to vaccine 526 development with companies (e.g., asthma, allergic rhinitis, atopic dermatitis, etc.) was not 527 considered either a direct or indirect conflict, but such involvement was disclosed. The 528 development of this guidance did not include any industry input, funding, or financial or non-529 financial contribution. No member of the guidance panel received honoraria or remuneration for 530 any role in the guidance development process. 531 532

A primary draft, inclusive of four focused questions, was iteratively developed by the senior 533 authors (MG, MS, EA, DG, DC, DK) using the Grading of Recommendation, Assessment, 534

Development, and Evaluation (GRADE) format for evidence synthesis from an individual 535 perspective with secondary consideration for the healthcare perspective. This draft was circulated 536

and revised/edited iteratively over multiple draft versions by the workgroup. A modified Delphi 537 panel among the members was used to rate agreement and consensus with the final 538 recommendations. 29 GRADE methodology is explained in detail elsewhere, 30-32 and the full 539 details of the methods for this analysis are detailed in the EMethods. An electronic REDCap 540 survey (Research Electronic Data Capture, Nashville, TN) was sent to panel members who were 541 asked to rate their level of agreement with recommendations (1=strongly disagree, 2= disagree, 542 3=neutral, 4=agree, 5=strongly agree). 33 Additionally, panel members were encouraged to 543

submit free text comments for statements, and could choose "not applicable" if they did not feel 544 they had the expertise to answer a question. A priori consensus was defined as agreement of 545 >75% for recommendations; "strongly disagree" and "disagree" were grouped together and 546 J o u r n a l P r e -p r o o f "strongly agree" and "agree" were grouped together. For recommendations in which consensus 547 was not achieved after the initial survey, an iterative discussion was undertaken with the intent to 548 resolve the key points and adjust language. Subsequent surveys were then sent to panel members 549

incorporating the de-identified responses from the prior survey with the goal of reaching 550

consensus. This process was repeated until consensus was reached or, if no consensus was 551 achieved by the 3 rd round, the statement was categorized as "no consensus reached." An 552 authorship statement detailing author roles can be found in the EMethods. 553 554

Outcomes prioritized in this systematic review and meta-analysis were anaphylaxis to the 555 vaccine and vaccine excipients, as well as the diagnostic accuracy of allergy testing to the 556 vaccine and vaccine excipients. The literature searched included (1) Global coronavirus 557 databases for country by country vaccine allergy or anaphylaxis reporting (2) national passive 558 vaccine safety reporting systems, and (3) Pub Med/Medline and clinical trials registries related to 559 SARS-CoV-2 vaccine clinical trials and published case series related to SARS-CoV-2 vaccine 560 adverse events. Systematic reviews and literature searches (supplement) were conducted by 5 561 authors (MG, MS, DC, AWB, AB) using Covidence (Cochrane Group, Brighton, UK). Searches 562 and manuscript selections are detailed in the PRISMA diagrams in Figure E1 . Specific inclusion 563 and exclusion criteria for each search are detailed in the EMethods. We considered but did not 564 rely on indirect evidence from similar event reporting from other vaccines given differences in 565

the context and technology of the vaccines. However, we considered indirect evidence for 566 management strategies of those with vaccine allergy as this comprises the extant literature 567 regarding vaccine allergy, and the acute management of severe allergic reactions, including 568 anaphylaxis, to vaccines is sufficiently similar to the experience with diagnosis and management 569 of anaphylaxis to foods, drugs and insect stings. We used the European Commission Guidance 570

for Industry of Adverse Drug Reactions threshold for what was considered a rare event as 571 between 1 case per 1,000-10,000 individuals, and very rare as < 1 case per 10,000 individuals. 34 572

While not systematically reviewed, we examined vaccine efficacy as an outcome as this was 573 identified as being of major importance to patients. 574 575 We use the wording "we recommend" for strong recommendations and "we suggest" for 576 conditional recommendations. The implications of the recommendation strength are presented in 577 Table E1 , the certainty of evidence in Table E2 , and the risk of bias assessment in Figures E2-4. 578 The final list of recommendations was developed by panel discussion and consensus. We present 579 the guideline statements and recommendations in Table 1 . The Evidence to Decision Framework 580 supplement provides a summary reflection of the evidence in the context of the clinical 581 recommendation. The results of the modified Delphi panel for each recommendation are shown 582 in the Table E3 . 583 584

Results: 585

Part 1: Recommendations for individuals before their initial SARS-CoV-2 vaccination who 586

do not have a history of a severe allergic reaction, including anaphylaxis, to SARS-CoV-2 587 vaccine or its excipients 588 589

Question 1: What is the risk of a severe allergic reaction, including anaphylaxis, to a SARS-590

CoV-2 vaccine in a patient with no history of a severe allergic reaction to a SARS-CoV-2 591 vaccine or its excipients? 592 593 Recommendation 1: 594 For patients with no history of a previous severe allergic reaction to a SARS-CoV-2 vaccine or 595 its excipients, the risk of SARS-CoV-2 vaccine-induced anaphylaxis is very rare and we 596 recommend vaccination over no vaccination based on this risk. 597

Strong Recommendation; High Certainty of Evidence 598 599

Recommendation 2: 600

For patients with a history of a severe allergic reaction, including anaphylaxis, unrelated to a 601 SARS-CoV-2 vaccine or excipient, the requirement for additional observation beyond standard 602 wait time (e.g. recommended by local health authorities for the general population) provides a 603 minimal absolute risk reduction in severe allergic reaction outcomes and may also contribute to 604 vaccine hesitancy. Therefore, we suggest against prolonged observation in those with a history of 605 severe allergic reactions unrelated to a SARS-CoV-2 vaccine or excipient. 606

Conditional Recommendation; Low Certainty of Evidence 607 608

Rationale 609

Systematic review and meta-analysis: 610 We searched the World Health Organization (WHO) Global Coronavirus database, the COVID 611 vaccine RCT living evidence map, government websites, medical literature, and press releases 612 for all estimates of anaphylaxis induced by SARS-CoV-2 vaccines up to March 19, 2021, 613 identifying 46 total reports meeting inclusion criteria (see EMethods). 10, 27, We performed a 614 random effects meta-analysis of proportions using hierarchical logistic regression and Clopper-615

Pearson CIs. Among 26 reports involving reported cases adjudicated to meet BCC for 616 anaphylaxis with a sample size of at least 20,000 doses, the meta-analyzed incidence of 617 anaphylaxis was 7.91 (95%CI 4.02-15.59) per million, and no anaphylaxis-related fatalities were 618

reported. In multivariable meta-regression, we found that reports of anaphylaxis without 619 adjudication were associated with a higher reported rate of anaphylaxis (OR 5.53, 95%CI 4.01-620 7.61) and compared to mRNA-based vaccines, lower rates of anaphylaxis were associated with 621 vaccines using adenoviral-vectors (OR 0.47, 95%CI 0.33-0.68) and inactivated virus (OR 622 0.31,95%CI 0.18-0.53). Findings were similar when analyzing all 46 reports (e.g., regardless of 623 sample size). (Figure 2 ). Table E2 details the certainty of evidence for this estimate, and Figure  624 E2 the risk of bias assessment. reactions, including anaphylaxis, may occur with SARS-CoV-2 vaccination, this is a rare event 663

and represents a very low (but not completely absent) risk according to pooled adjudicated 664 data. 26 In formulating recommendations 1 and 2, we weighed the potential benefits and harms of 665 vaccination against each other, along with consideration of patient values, preferences, and cost. 666

While we acknowledge that well-informed individuals may have values and preferences that 667 could lead to vaccine refusal in spite of very high-certainty of evidence regarding the rarity of 668 severe allergic reactions to these vaccines, it was felt that most informed individuals would be 669 highly likely to choose vaccination over vaccine refusal based on the very rare risk of a severe 670 allergic reaction and the benefit of vaccination in this situation. 671 672

Risk-Stratification Based on Allergic History 673

In the phase 2 and 3 clinical trials for the currently approved vaccines, participants were 674 excluded from participation if they had a known or suspected allergy or history of anaphylaxis, 675 urticaria, or other significant adverse reaction to the vaccine or its excipients, including 676 polyethylene glycol (PEG) and polysorbate 80, but not for any other baseline allergic or atopic 677 condition. 4, [8] [9] [10] [11] 50, 71, 73, 88 Of note, a high percentage of individuals reporting severe allergic reactions 678

to the SARS-CoV-2 mRNA vaccines in the CDC reports also had a self-reported history of an 679 underlying allergic condition including past medication and unrelated vaccine allergy, and were 680 female; however, the significance and validity of these allergy diagnoses or male/female 681 differences are difficult to assess if these signify a risk signal or not. 22, 24, 89 Allergic conditions are 682 very common in the general population and self-reported allergy is typically much higher than 683 confirmed allergy. As well, the rate of individuals with similar allergic comorbidity who 684 successfully tolerated their vaccine has not been calculated, and this is needed to properly 685 J o u r n a l P r e -p r o o f quantify a risk ratio related to a general or specific type of allergic history (or sex). 686

Mechanistically , it is unclear why allergies to food, venom, or other non-PEG/mRNA containing  687  vaccines/medications would pose any hazard requiring additional post-vaccination observation  688  or contraindication to vaccine administration. Therefore, pending emergence of additional data  689 showing there is a clearly increased risk relative to a control population, allergic or atopic 690 comorbidity should not be considered a risk greater than the general population for a vaccine-691 associated allergic reaction, and inclusion of these precautions risks harm in promoting vaccine 692 hesitancy. 14, 18, 90 There is an ongoing study that is exploring risks of SARS-CoV-2 vaccination 693 related to allergic co-morbidity (www.clinicaltrials.gov, NCT04761822 As shown in Figure 1 , multiple international public health agencies and allergy organizations 712 around the world have issued guidance related to concerns for severe allergic reactions 713 specifically to the mRNA vaccines that generally echo the CDC recommendations. Many also 714 emphasize shared decision making and all suggest consideration of allergy-immunology 715

consultation. Most lack explicit language formally recommending testing to excipients 716 (including PEG) or the vaccine itself as part of the evaluation (due to the absence of evidence 717

and predictive values for the testing). 90, 95 Only the Australasian Society of Clinical Immunology 718

and Allergy (ASCIA) and World Allergy Organization (WAO) suggest consideration for skin 719 testing to the vaccine or its components (e.g., PEG, polysorbate) in some cases. 8, 25 A 720 recommendation for such patients to undergo evaluation by an allergist may or may not imply 721 consideration for testing as part of this evaluation, though the nature of what should be part of 722 such evaluation is not specified. Threshold agreement was achieved for the voting on these 723 recommendations on the first round of voting (Table E3)  724  725 Question 2: In patients without a history of a severe allergic reaction, including anaphylaxis, to a 726 SARS-CoV-2 vaccine or its excipients, should allergy skin testing to SARS-CoV-2 vaccines or 727 its excipients be performed? 728 729 Recommendation 3: 730 In patients with no history of a severe allergic reaction, including anaphylaxis, to SARS-CoV-2 731 vaccines or its excipients, we recommend against vaccine or vaccine excipient testing prior to 732 vaccination in an attempt to predict the rare individual who will have a severe allergic reaction to 733 vaccination. for pooling, we presumed all cases in the Abrams et al report were anaphylaxis, and the 750 combined incidence rate between these studies is 0.15 cases per million person-years ( Figure 3 ). 751

No studies describing a polysorbate allergy rate were identified. rare. In addition, data regarding population-based skin test screening using SARS-CoV-2 vaccine 766 are sparse--only one published study detailing SARS-CoV-2 prick testing prior to initial 767 vaccination for persons (who had not yet received SARS-CoV-2 vaccine) with a general history 768 of anaphylaxis, which noted no positive skin tests. 97 The very rare rate of adjudicated cases of 769 SARS-CoV-2 vaccine anaphylaxis and a lack of evidence that COVID-19 vaccine reactions are 770 attributable to PEG or polysorbate, strongly suggests against any population based approach that 771 would involve screening for pre-existing specific-IgE against PEG or polysorbate as a means to 772 predict risk of a severe allergic reaction to a SARS-CoV 2 vaccine. 14,18 Threshold agreement was 773 achieved for the voting on this recommendation on the first round of voting (Table E3) true negative, 1 false positive). However, the specificity may be falsely high due to the case 804 series/report study designs. As well, among the reports, not all patients were challenged to 805 confirm the history of PEG reaction, the diagnostic gold standard, which lowers the certainty of 806 evidence due to indirectness of the testing. There were 6 reports detailing 7 total patients with 807

suspected allergy to polysorbate that had skin testing (no false positives, and 57 controls tested 808 that were non-reactive). [111] [112] [113] [114] [115] [116] Polysorbate testing sensitivity/specificity were not calculated 809

given the low number of patients tested. Table E2 details the certainty of evidence for this 810 estimate and Figure E4 the risk of bias assessment. 811 812

The same systematic review identified no studies that investigated vaccine or excipient testing 813 compared to negative controls in individuals with a known or suspected allergic reaction of any 814 severity to a SARS-CoV-2 vaccine. However, 4 case reports (without controls) were identified 815 describing testing with SARS-CoV-2 mRNA vaccine or PEG/polysorbate in persons with 816 reported severe allergic reactions to the vaccine, and vaccine testing in negative controls to 817 establish a non-irritating testing concentration. 117,118 119 The first report details negative vaccine 818 skin testing among 4 persons with reported allergic reactions to their initial vaccination, 3 of 819 whom elected to receive a second dose and did so without reaction. 118 The second report details 820 negative PEG 3350 testing in 8 persons with reported allergic reactions their initial vaccine, 7 of 821 whom elected to receive a second dose and did so without reaction; as well as negative 822 polysorbate 80 testing in 6/7 persons tested prior to their initial vaccination, with all 6 receiving 823 their initial dose without reacting. 117 The third report details no irritant response detected among 824 55 negative controls tested to SARS-CoV mRNA vaccine. 119 The fourth detailed 2 adult patients 825 with severe allergic reactions to their initial mRNA (Moderna) vaccine, who underwent skin 826 testing to PEG, polysorbate, and the mRNA vaccine itself. In both patients, excipient skin testing 827 was negative but intradermal skin tests to the Moderna vaccine were positive. However, both 828 tolerated graded dosing administration of the vaccine without issue. 120 Lastly, one case report of 829 PEG testing was identified in a female patient with a past history of skin and oropharyngeal 830 reactions to PEG containing products, who sought evaluation after experiencing a reported 831 systemic reaction to her initial dose of the Pfizer-BioNTech vaccine that was treated with 832 epinephrine but was not associated with tryptase elevation. While undergoing testing, 833

approximately 12 minutes after PEG 4000 prick skin test was applied, she developed a multi-834 system systemic reaction treated with epinephrine treatment, which also was not associated with 835 tryptase elevation. Skin testing to the Pfizer-BioNTech vaccine and to PEG MW less than 4000 836 were all negative, and neither vaccine re-challenge nor challenge to PEG 4000 or any other 837 molecular weight PEG were attempted. 121 One additional case report was noted regarding an 838 atopic female with a past episode of urticaria attributable to a topical product possibly containing 839 PEG, who developed an erythematous rash, then slurred mouth and hoarseness over the course of 840 5 hours post her initial Pfizer-BioNTech vaccine (though had no symptoms at 30 minutes). Her 841 serum tryptase level was normal, and this reaction occurred despite steroid premedication 842 starting 14 hours before vaccination and antihistamine an hour before vaccination. During 843 evaluation by an allergy specialist 2 weeks after the event, while no PEG or vaccine skin testing 844 was reported, she was noted to have an elevated basophil activation test (14.79 CD203c high %) to 845 PEG 4000 at 0.2mg/mL (and no activation seen in 5 negative control patients). 122 846 847

Discussion: PEG-2000 is speculated to be a potential culprit in allergic reactions to SARS-CoV-848 2 mRNA vaccines. 14,123 PEG and polysorbate are ubiquitous compounds, found in many health 849 and beauty products and in foods and beverages, and are routinely used and tolerated in daily 850

life. 14 There are limited case reports in the medical literature of allergic reactions attributable to 851 PEG contained in therapeutic agents and radiocontrast media. 15, 16, 98, [124] [125] [126] PEG is available in 852 different molecular weights and structural formats. Allergic reactions may be more likely with 853 higher molecular weight (MW) PEG agents, higher concentrations, or parenteral administration. 854

It is uncertain if the concentration and MW of PEG in SARS-CoV-2 mRNA vaccines would be 855 sufficient to cause reactions 15,16 There is theoretical concern, but limited evidence, that PEG may 856 cross-react with certain polysorbates. 16 Polysorbate-80 in adenovirus-vector vaccines was not 857 implicated as causing allergic reactions in their trials, and there is limited reporting of allergic 858 reactions of any severity with these vaccines. 859 860

Evaluation for suspected PEG allergy is largely based on history. Use of high MW PEG 861 solutions as skin testing agents has not consistently demonstrated the ability to elicit wheal and 862 flare responses, and it remains unclear if this approach would reliably indicate the presence (or 863 absence) of specific IgE. 125 In this meta-analysis, the pooled sensitivity of PEG skin testing is 864 only 58.8%, but the pooled specificity is 99.5%, which implies that the test will miss identifying 865 the presence of PEG-specific IgE in a significant number of PEG allergic patients, but non-PEG 866 allergic individuals do not appear to have falsely positive tests. There have been few cases of 867 anaphylaxis reported to intradermal skin testing, mainly using PEG with MW>3000. Other non-868 validated methods of detection for PEG-induced allergic response have been described, as has 869 PEG oral provocation challenge. 15, 16, 98 In individual with a high pre-test probability of PEG 870 allergy, testing to PEG, from these data in the meta-analysis show a very uncertain (very serious 871 risk of bias) high positive likelihood ratio to confirm the diagnosis. However, this is distinct 872 from the suggestion that PEG testing can inform the likelihood of a SARS-CoV-2 vaccine 873 reaction (very serious indirectness). This was noted in case series to date where 10 persons who 874 reacted to their mRNA vaccine in fact had negative PEG skin testing, and where 2 patients 875 additionally were skin tested to PEG as well as to both polysorbate (negative) and the Moderna 876 vaccine (positive intradermal test) and tolerated re-administration. 117, 120 In the case of a person 877 with a mRNA vaccine reaction where PEG sensitization was detected, this was only to PEG 878 4000, and not the vaccine or the concentration of PEG in the vaccine. There is not yet any 879

convincing evidence to confirm PEG as a causative agent in the reported SARS-CoV-2 mRNA 880 vaccine reactions and the diagnostic utility of PEG and polysorbate allergy testing is highly 881 uncertain. 14,18,90,123 Of note, skin testing to the vaccines is not approved under any of the EUAs. 882

Further research regarding excipient and vaccine skin testing in this context is needed. 883 884

Other mechanisms might potentially cause allergic symptoms following administration of SARS-885

CoV-2 mRNA vaccines. Complement Activation-Related Pseudoallergy (CARPA) has been 886 theorized as a possible mechanism, in particular with lipids used in drug delivery. 127 128 mRNA 887 particles themselves may also potentially be a causative agent, acting as a direct mast cell 888 degranulation agent. There is one report that trometamol, a buffer specific to the Moderna 889 vaccine, was associated with anaphylaxis to gadolinium-based contrast agents, also by a direct 890 degranulation mechanism. 129 Toll Like Receptors (TLR) 3,7, and 8 can be directly activated by 891

double-stranded and single-stranded RNA particles from viruses, and can cause mast cell 892 degranulation. 130, 131 Although the likelihood of such events from a SARS-CoV-2 mRNA vaccine 893

is unclear, these pathways should be considered among the potential mechanisms for allergic 894 reactions to these vaccines. 132 895 896

Caution should be exercised in considering excipients as a provoking cause of vaccine reactions. 897

While excipients have occasionally caused allergic reactions with other vaccines, historically 898 many excipients have also been wrongly implicated based on theoretical rather than actual risk, 899 most prominently egg (ovalbumin) in modern influenza vaccines. 75, 96, 133 This may be due to 900 excipient concentrations being well below a threshold necessary to provoke a reaction. 134, 135 This 901 may also prove to be the case for excipients that are suspected triggers for the SARS-CoV-2 902 vaccine reactions. 903 904

There is one published approach for SARS-CoV-2 mRNA vaccination with guidance based on 905 skin testing to excipients. 14,18 Notably, if methylprednisolone acetate is used for testing, the 906 clinician should be aware this may contain both PEG and Polysorbate 80, and should test only 907

with brands of methylprednisolone that do not also contain Polysorbate 80. 14 The clinician 908

should also be aware that the quantity of PEG administered by intradermal testing using this 909 agent could exceed the quantity of PEG in the Pfizer-BioNTech mRNA vaccine, which only 910 contains 0.05mg PEG-2000 per dose (Table E6) . Therefore, even in persons with known PEG 911 allergy who have positive PEG skin testing, it is likely that graded or full dose SARS-CoV-2 912 mRNA vaccine would be well tolerated if no systemic allergic reaction occurred during skin 913 J o u r n a l P r e -p r o o f testing. The positive PEG test is less problematic to interpret, given this specificity, but no data 914 exists to specify that positive PEG sensitization definitively infers a significant risk that such 915 patients will not tolerate PEG-containing vaccines. As such, there is no clear role for the use of 916 skin testing to PEG to inform a decision to withhold the vaccine or not, which is consistent with 917 the last published vaccine allergy practice parameter which suggests excipient or vaccine 918 sensitized individuals should be offered a graded dose challenge or multi-step desensitization 919

instead of withholding the vaccine. 14,96 Data regarding skin testing to SARS-CoV-2 vaccine 920 itself are scant. There are a small number of patients with suspected SARS-CoV-2 vaccine 921 reactions who have undergone vaccine testing, most with negative results, but all who were 922 willing to receive a second dose tolerated it without reaction irrespective of positive vaccine skin 923

testing. 117,118,120 The 3 individuals with a history of mRNA reaction with sensitization to either 924 the vaccine or PEG either declined or were not offered the opportunity to receive a second dose. 925

If vaccine testing is to be performed in persons hesitant to proceed with vaccination, the vaccine 926

should be prepared per manufacturer instructions with regard to storage, thawing, and diluting 927 for reconstitution. Consistent with the last published vaccine practice parameter, patients with 928

positive skin testing to a SARS-CoV-2 vaccine may receive vaccination through graded or full 929

dosing (see below). 120 Limited safety data are available for testing to the vaccine or the vaccine 930 excipients in this context. Further details regarding international variation about 931 recommendations for vaccine/excipient testing are detailed in Figure 1 . 932 933

While testing may be considered as a preference-sensitive option in shared decision-making, 934

options for cautious administration of vaccine ( Figure 4) pre-medication prior to vaccination as it has low certainty evidence in preventing anaphylaxis, 1007

and theoretically corticosteroid pre-medication could diminish the immune response. 1008

Conditional Recommendation; Low Certainty of Evidence 1009 1010

Recommendation 11: We recommend in favor of globally coordinated research studies being 1011 conducted to address i) vaccine and vaccine excipient testing diagnostic accuracy for allergy to 1012 SARS-CoV-2 vaccines; ii) administration of the vaccine to individuals with prior anaphylaxis to 1013 the vaccine or vaccine excipient; iii) the necessity and efficacy of graded vaccine administration 1014

in the context of a patient with possible SARS-CoV-2 vaccine allergy; iv) the safety, efficacy, 1015

and necessity of mixing SARS-CoV-2 vaccine platforms; and v) the incremental benefit of 1016 additional doses of an mRNA or certain adenovirus-vector vaccines following an initial dose. 1017

Research Recommendation 1018 1019

Rationale/Discussion: Almost all allergy organizations recommend that the routine 1020 administration of SARS-CoV-2 vaccines are contraindicated in individuals with a suspected 1021

immediate allergic reaction to the SARS-CoV-2 vaccines or their components (i.e., PEG or 1022 polysorbate 80), although all allow consideration of referral to an allergist-immunologist to 1023 determine the likelihood the initial reported reaction was consistent with an allergic reaction of 1024 any severity, and if so, if a SARS-CoV-2 vaccine can be safely administered. (Figure 1 investigates the nature and timing of the reported reaction, and carefully considers the nature of 1048 the reported symptoms and whether they are the result of an immune mediated process and not 1049 the result of any mimicking condition that could be the result of a non-allergic process. This step 1050 alone is of critical importance and may represent the greatest value that the allergist can offer as 1051 an expert in such evaluation. Also critical to involvement of the allergist in this process is for the 1052 persons providing vaccination to be trained to ask questions regarding risk of reaction and help 1053 facilitate referral to the allergist if there is a contraindication to receiving a dose, or in the case of 1054 a suspected allergic reaction occurring at their site. If possible, patients with a history of a 1055 possible allergy to PEG, polysorbate, other vaccines, or even their initial SARS-CoV-2 vaccine 1056

should be encouraged to be proactive in discussing this with their primary care provider before 1057 seeking initial or additional SARS-CoV-2 vaccine doses. 1058 1059

The 2012 relative to other infectious diseases in terms of the global burden of this disease, and an 1077 imperative international public health need to attain herd immunity through vaccination. Any 1078 potential for vaccine refusal or the vaccine being withheld in a pandemic must be approached 1079 from an ethical perspective which considers whether SARS-CoV-2 infection and viral 1080

propagation are riskier outcomes than vaccination in a setting where severe allergic reactions can 1081 be managed. 145 While no single best choice in these contexts exists, it can be addressed through 1082 an individualized, shared decision-making approach reviewing treatment options and the risk-to-1083 benefit trade-offs related to vaccine reactions vs. SARS-CoV-2 infection risk. Regardless of how 1084 the vaccine is administered, we recommend against routine pre-medication prior to vaccination 1085

(particularly with glucocorticosteroids) as it has low certainty evidence in preventing 1086 anaphylaxis, and glucocorticosteroid pre-medication (or glucocorticosteroid treatment of any 1087

suspected allergic reactions to SARS-CoV-2 vaccines including anaphylaxis) could diminish the 1088 immune response. 146,147 1089 1090 Figure 4 outlines preference-sensitive approaches to the individual who had an allergic reaction 1091

to the initial dose of the vaccine. The allergist role here is central as well in helping a patient 1092

clarify their values as to their choices and the outcomes of those choices in proceeding with or 1093 declining vaccination. This process is highly distinct from evaluating someone with a history of 1094 allergy to a vaccine excipient, who has not yet received the initial vaccine. These approaches are 1095 only recommended for trained experts in the diagnosis of medication allergy (including allergic 1096 reactions to vaccines and medication provocation challenge), in facilities staffed with personnel 1097 skilled and trained to be able to assess and treat an allergic reaction resulting from testing or 1098 vaccine administration. Resources must be available to provide direct observation of patients for 1099 a minimum of 30 minutes after the vaccine is administered. The outlined approaches all involve 1100 some degree of trade-off, and the ultimate choice must be informed by the values, goals, and 1101 preferences of patients. These issues must be balanced against increased infection risk, with 1102 increased morbidity and mortality, which becomes a risk from vaccine refusal or withholding 1103

vaccination. Graded vaccine challenge does offer some practical reassurance to the patient and 1104 clinician reluctant to proceed with single-dose vaccination, though full dose vaccination may be 1105 just as safe as a graded approach in many circumstances. In resource limited settings or if 1106 consultation with an allergy specialist is not readily available, such as in rural settings or in low-1107

and middle-income countries, such shared decision-making does not need to be exclusively 1108 provided by a specialist. While specialist referral would be preferred any clinician may engage 1109 the patient in shared decision-making based on the options in Figure 4 , allowing for local context 1110 in decision making, with input to the patient from the practitioners who are trusted by the local 1111

population. In particular, if first dose protection of any SARS-CoV-2 vaccine is high, or there is 1112 availability of an alternative vaccine platform, particular preference may be given for vaccine 1113 refusal/withholding the vaccine or administering this alternative agent in certain local and 1114 regional settings. 1115 1116

Experience with graded challenge with SARS-CoV-2 mRNA vaccines is limited at present to 1117 one very small case series. The efficacy of graded vaccination is unknown, though one report 1118 has shown this can be successful. 120 It is unknown if splitting doses and/or diluting the vaccine 1119 outside of the initial manufacturer recommendation would disrupt the vaccine integrity or impair 1120 immune response. However, these variables may potentially contribute to unforeseen issues in 1121 trying to adapt previously recommended approaches for vaccine administration where there is 1122 concern of possible allergy, rendering this option for graded-dose administration less preferable 1123 than single-dose administration. 96 Switching from one vaccine platform to another is an 1124 additional alternative to consider in this decisional matrix that may reduce reliance on graded-1125 dosing and may be a more feasible office-based choice, which is endorsed by a number of 1126 international regulatory health agencies where multiple vaccine options are approved ( Figure  1127 1). 139 1128 1129

The evaluation of individuals with a known or suspected PEG allergy (including anaphylaxis) 1130 but who have not yet received a vaccine is distinct. An algorithm for excipient testing has been 1131

published, but without evidence that the vaccine excipients are the cause of any vaccine 1132 reactions, or that excipient allergic/sensitized individuals cannot tolerate the vaccine. Our meta-1133 analysis suggests skin testing to excipients as a screening measure prior to vaccination has low 1134 sensitivity and is unlikely to reliably identify persons at risk. A choice to test and then 1135 recommend a sensitized person not receive an mRNA vaccine could unnecessarily withhold an 1136 intervention based on speculation of risk, or force choice of an alternative vaccine platform (if 1137 available) that may have different non-immunologic risks. However, this could be a preference-1138 sensitive option that concerned patients elect, and a negative skin test could be viewed as 1139 reassuring to proceed with use of an mRNA vaccination, despite the test having poor sensitivity. 1140

Similarly, it is reasonable to administer an mRNA vaccine following a shared decision-making 1141 process with an allergy specialist, either as a single or graded dose, or to provide an adenovirus 1142 vector vaccine (with precaution given polysorbate content) without testing. For individuals with 1143 a polysorbate allergy, it is reasonable to administer an adenovirus vector vaccine following a 1144 shared decision-making process with an allergy specialist, either as a single or graded dose, or to 1145 provide an mRNA vaccine (with precaution given PEG content) without testing. Either vaccine 1146

should be given in a setting where the patient can be monitored for up to 30 minutes after 1147 vaccination and that is staffed and equipped to treat potential vaccine-associated anaphylaxis. 1148 1149

Withholding or refusing a second dose of an mRNA vaccine (either Moderna or Pfizer-1150 BioNTech) has been considered by some, in the belief that the initial dose will provide adequate 1151

protection. Although we lack precise estimates of what constitutes durable protective adaptive 1152 immunity post-vaccination, data from the EUA suggest there is >50% protection at >2 weeks 1153 after the first dose (prior to administration of the second dose). Israeli reports suggest 33% to 1154 60% protection more than 2 weeks after the first dose up to the time of the second dose. 148 1155

Additional studies have suggested first-dose protection of up to 93% but with wide ranges of 1156 protection reported. 9, 60, 92, 94, [149] [150] [151] However, the duration of this partial protection is unknown, 1157 but likely shorter-lived than the immunity achieved after 2 doses or achieved naturally from 1158 SARS-CoV-2 infection. Optimal longer-term protection would be ensured by complete 1159 vaccination. Partial immunity at a community level is of concern because it might theoretically 1160 enable the spread of more virulent variants of the virus. Even within a shared decision-making 1161 paradigm, vaccine refusal or withholding a vaccine should remain an option of last resort, and all 1162 steps taken to avoid this outcome. Withholding/refusal, if chosen, should be clearly documented 1163

in the medical record, and the decision to do so made collaboratively by the patient after having 1164 been provided data regarding the nature of the risks. 92 1165 1166

Threshold agreement was achieved for the voting on these recommendations on the first round of 1167 voting (Table E3).  1168  1169 This document has several limitations. First, SARS-CoV-2 vaccination is a new and evolving 1170 topic, and data to date regarding allergic reactions, potential provoking causes of these reactions, 1171

and best management practices are limited. As such, there is intent to continue to re-evaluate and 1172 update these recommendations as more data are published regarding reactions and their 1173 management. Second, GRADE is one evidence rating approach, and has well-described 1174

limitations. Third, in this context, several recommendations are conditional, and have low 1175 certainty of evidence, which underscores the first limitation. This in particular may impact 1176 recommendations regarding excipient and/or direct vaccine testing, as well as considerations 1177 about withholding/refusing vaccination (initial or subsequent doses) or the best initial choice of a 1178 vaccine given a patient's history. Fourth, to perform the meta-analysis and data pooling for 1179 questions 2 and 3, we made two major assumptions: i) we considered all reactions coded in a 1180

Canadian drug allergy database as allergy to PEG or PEG containing medications as 1181 anaphylaxis; and ii) we considered any positive PEG skin test, by any method (prick or  1182 intradermal), to any listed concentration, as the same for the purposes of denoting a positive 1183 result to assess testing sensitivity and specificity. Both these assumptions allow for a liberal 1184 consideration of what defines a case, and increases the potential sensitivity of the analysis, at the 1185 risk of inflating both estimates. However, given limited data, we feel these are justified. Fifth, 1186

while our approach and recommendations were developed through systematic evidence 1187 synthesis, in some instances these recommendations contradict more empiric approaches from 1188 allergy professional societies and governmental health authorities. It is of note that no approach 1189 J o u r n a l P r e -p r o o f or recommendation-ones made in this document or made previously by any society or 1190 governmental health authority-have been proven safe by high certainty of evidence in the 1191 context of evaluating suspected allergic reactions to these vaccines. Lastly, our 1192 recommendations may be limited to the populations that have been studied. Our approaches and 1193 considerations may be more or less relevant in particular countries or regions, depending on 1194 government policy, access to vaccination, access to allergy specialists for evaluation of potential 1195 reactions, and availability of resources for some of the options in our shared decision-making 1196 paradigm. In this analysis, there were no studies identified that addressed this issue in the 1197 context of low to middle income areas or resource-limited areas, and most of the studies on 1198 vaccine anaphylaxis are from tertiary care centers, which by definition are areas with access to 1199 specialty care, including allergists. In areas without access to an allergist, remote healthcare 1200 options or involvement of a healthcare provider who can assess and manage vaccine reactions 1201 could be considered, though this does not address individuals without access to care or locations 1202 lacking in some of the resources described. It is possible that recommendations made by an 1203 allergy specialist who is not actually administering the vaccine, to another care provider who is 1204 doing so, may not necessarily be accepted by others who may have less experience in treating 1205 anaphylaxis, or with administering a vaccine to someone who has been evaluated for a vaccine-1206 associated allergic reaction. These factors may modify the recommendations stated. The 1207

Evidence to Decision Framework supplement provides a summary reflection of the evidence in 1208 the context of the clinical recommendation and helps balance the recommendations in light of 1209 these limitations. 1210 1211

Conclusion 1212 SARS-CoV-2 is a devastating global pandemic with limited treatment options, which has caused 1213 >3,000,000 global fatalities and >$10 trillion in global economic costs. 3 To achieve an optimal 1214 population herd immunity and mitigate the devastating impact of this infection, vaccination 1215

represents the optimal global strategy. Multiple vaccines have proven to be safe and effective in 1216 clinical trials and are now in use. Potential allergic reactions, including anaphylaxis, have been 1217

reported, but these have occurred very rarely. No uniform recommendations exist on an approach 1218 to the assessment and management of individuals with a known or suspected allergy to the 1219 excipients or the vaccine itself. This document provides evidence-based (where available) expert 1220 consensus that incorporates guidance from clinical specialists in Australia, Canada, Europe, 1221

South Africa, the United States, and the United Kingdom stressing a patient-centered approach 1222

involving consideration of the risks and benefits of receiving COVID-19 vaccination, the value 1223 and cost-effectiveness of testing and precautionary measures, and shared decision-making in 1224 recognition of multiple preference-sensitive approaches to this issue from an international 1225

perspective. There is no clear evidence that any pre-existing factor, or testing with the vaccine or 1226 excipients, can predict risk of reaction to the vaccine. As this is the first experience with these 1227 vaccines, this is intended to be a living document that will require periodic updating due to still 1228 emerging needs assessment, including further research data on the nature of vaccine-associated 1229 reactions and the necessity of potential risk-assessment measures. There are continued 1230 knowledge gaps and unmet needs outlined in Table 4 that must be addressed as the vaccine 1231 rollout continues. Given an imperative global need to vaccinate as many people in as many 1232 countries as possible, the clinician should be familiar with the risk of potential reactions to these 1233 vaccines, and the approach to their evaluation and management. 1234 1235 J o u r n a l P r e -p r o o f Evidence Certainty What is the risk of SARS-CoV-2 vaccine anaphylaxis in a patient with no history of anaphylaxis to a SARS-CoV-2 vaccine or its excipients?

For patients with no history of a previous severe allergic reaction to a SARS-CoV-2 vaccine or its excipients, the risk of SARS-CoV-2 vaccine-induced anaphylaxis is very rare and we recommend vaccination over no vaccination based on this risk.

For patients with a history of a severe allergic reaction, including anaphylaxis, unrelated to a SARS-CoV-2 vaccine or excipient but no history of a previous severe allergic reaction to a SARS-CoV-2 vaccine or its excipients, the requirement for additional observation beyond standard wait time (e.g., recommended by local health authorities for the general population) provides a minimal absolute risk reduction in severe allergic reaction outcomes and may also contribute to vaccine hesitancy. Therefore, we suggest against prolonged observation in those with a history of severe allergic reactions unrelated to a SARS-CoV-2 vaccine or excipient.

In patients without a history of anaphylaxis to a SARS-CoV-2 vaccine or its excipients, should allergy skin testing to SARS-CoV-2 vaccines or its excipients be performed?

In patients with no history of a severe allergic reaction, including anaphylaxis, to SARS-CoV-2 vaccines or its excipients, we recommend against vaccine or vaccine excipient testing prior to vaccination in an attempt to predict the rare individual who will have a severe allergic reaction to vaccination.

In patients with a history of anaphylaxis to a SARS-CoV-2 vaccine or its excipients, should allergy skin testing to SARS-CoV-2 vaccines or its excipients be performed to determine if vaccine withholding is needed?

We suggest against the clinician routinely performing skin or in vitro testing using SARS-CoV-2 vaccines or excipients outside of the research setting for the purpose of vaccine withholding, given such testing has unknown sensitivity/specificity in predicting severe allergic reactions, including anaphylaxis, to SARS-CoV-2 vaccines.

Should SARS-CoV-2 mRNA or adenovirus vector vaccines be administered to an individual who had an immediate allergic reaction to the first dose of the vaccine (defined as a generalized, systemic allergic reaction with acute onset occurring within 4 hours of vaccine administration), or given as a first dose to an individual who is suspected to have reacted previously to an excipient ingredient that is also present in the SARS-CoV-2 mRNA or adenovirus vector vaccines?

We recommend a shared decision-making paradigm of care favoring vaccination through full or graded dosing (with or without additional observation time post-vaccination) or changing vaccine platforms to another agent over no vaccination because there is no single best approach to assessment and management of the patient with a suspected SARS-CoV-2 mRNA or adenovirus vector vaccine reaction, or the patient with an allergy to an excipient in either of these vaccines who has not yet been vaccinated.

In patients with suspected immediate allergic reaction to SARS-CoV-2 vaccine whose standard schedule requires more than one dose, we recommend referral to an allergist for assessment of additional vaccination over no vaccination/vaccination being withheld. In resource limited settings where specialist referral is not readily available, alternatives may be presented in a shared decision-making context to provide assessment and opportunity for vaccination by remote consultation, use of alternative vaccine products, or delay in vaccination until a solution can be determined.

In patients with a suspected or confirmed but remote past medical history of reaction to a vaccine excipient, we recommend referral to an allergist for assessment of additional vaccination over no vaccination/vaccination being withheld. In resource limited settings where specialist referral is not readily available, alternatives may be presented in a shared decision-making context to provide assessment and opportunity for vaccination by remote consultation, use of alternative vaccine products, or delay in vaccination until a solution can be determined.

In patients with a definite/confirmed recent allergic reaction to COVID vaccine and/or excipient, we recommend referral to an allergist for assessment of additional vaccination over no vaccination/vaccination being withheld. In resource limited settings where specialist referral is not readily available, alternatives may be presented in a shared decision-making context to provide assessment and opportunity for vaccination by remote consultation, use of alternative vaccine products, or delay in vaccination until a solution can be determined.

While all vaccines should be administered in facilities capable of treating anaphylaxis, particularly for individuals with a prior immediate systemic allergic reaction to a SARS-CoV-2 vaccine or vaccine excipient, we recommend the clinician should administer SARS-CoV-2 mRNA or adenovirus vector vaccine in a setting equipped to manage anaphylaxis (e.g. hospital, mass immunization clinic, specialist office), under the supervision of personnel trained in the recognition and management of anaphylaxis. In resource limited Strong Moderate J o u r n a l P r e -p r o o f settings where specialist referral is not readily available, alternatives may be presented in a shared decision-making context to provide assessment and opportunity for vaccination by remote consultation, use of alternative vaccine products, or delay in vaccination until a solution can be determined. We suggest against routine H1-antihistamine or systemic corticosteroid pre-medication prior to vaccination as it has low certainty evidence in preventing anaphylaxis, and theoretically corticosteroid pre-medication could diminish the immune response.

We recommend in favor of globally coordinated research studies being conducted to address i) vaccine and vaccine excipient testing diagnostic accuracy for allergy to SARS-CoV-2 vaccines; ii) administration of the vaccine to individuals with prior anaphylaxis to the vaccine or vaccine excipient; iii) the necessity and efficacy of graded vaccine administration in the context of a patient with possible SARS-CoV-2 vaccine allergy; iv) the safety, efficacy, and necessity of mixing SARS-CoV-2 vaccine platforms; and v) the incremental benefit of additional doses of an mRNA or certain adenovirus-vector vaccines following an initial dose.

J o u r n a l P r e -p r o o f 

Definitive identification of an immunologic mechanism for reactions Determination of a known excipient(s) as an allergen Determination of risk for receiving SARS-CoV-2 vaccines containing an excipient to which a recipient is allergic Determination of risk in receiving a second dose of a SARS-CoV-2 vaccine after an allergic reaction to the first dose Establish test sensitivity, specificity, and reliability for use of the vaccine and/or vaccine excipients as a testing reagent Accurate determination of the incidence of allergic reactions, including anaphylaxis Identification of potential risk factors associated with allergic reactions Necessity of testing or how test results may influence patient hesitancy to receive vaccination Necessity of single vs. graded/split dosing for risk-assessment Necessity of additional post-vaccination observation time for risk-assessment Efficacy of mixed vaccine platform schedule Stability of graded /split dosing for mRNA vaccines Determination of durable immunity conferred by 1 st dose of a vaccine to assist in determining risk/reward of additional doses Unmet Needs Consensus on reporting standards for anaphylaxis related to vaccines (Brighton Collaboration Criteria vs. NIAID or WAO criteria Development of an active surveillance system for vaccine reactions Preparedness and training of personnel at vaccination clinics to properly identify and treat potential anaphylaxis. Consideration for use of placebo dosing, under a shared decision-making paradigm, for determining validity of a reaction in patients with underlying anxiety Evidence-based algorithmic approach to individuals with reactions to the first dose of a SARS-CoV-2 vaccine or who have a history of SARS-CoV-2 vaccine excipient allergy Handling of assessment of patients with a vaccine reaction or an excipient allergy in settings where there is reduced access to specialist care or persons with experience in managing anaphylaxis (e.g., rural, low/middle income countries) Incidence per million doses These options are also considerations for patients wishing to receive a second dose of a SARS-CoV-2 mRNA vaccine without graded dosing. The green to red color gradient across and within each choice represents gradually increasing risk. There is no single best-choice approach to vaccinating an individual with a suspected history of an allergic reaction to a SARS-CoV-2 vaccine. There is a trade-off between potential subsequent risk of a reaction and the ability that can be safely managed, the risk of reduced efficacy from splitting the vaccine dose into two or more steps that may require dilution, and the risk of contracting SARS-CoV-2 infection as a result of having partial immunity resulting from deferring additional vaccine doses. The risks, benefits, and trade-offs should be thoroughly and carefully discussed with the patient, and the selected approach be made through a shared decision-making process. Alternative vaccine platforms may encourage use of options to give the vaccine with or without additional observation time, although use of combination SARS-CoV-2 vaccine platforms has not been well studied. Consult published guidance regarding how to interpret antibody titers or other immune markers post-vaccination. J o u r n a l P r e -p r o o f Figure E4 . Risk of Bias, Question 3

Author 

There is high confidence that the true effect lies close to that of the estimate of the effect.

There is moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low

There is limited confidence in the effect estimate. The true effect may be substantially different from the estimate of the effect.

There is very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect J o u r n a l P r e -p r o o f 2 Explanations a. Non-adjudicated rates yield estimates that are higher than adjudicated ones by about 5-fold. b. One adjudicated study yielded a markedly higher estimate than all others. It also was the only study that was not a national pharmacovigilance study. Though it contributed to some heterogeneity, it was not felt that this was so serious to rate down for inconsistency because the (1) estimate of effect was still rare, (2) excluding this study, yielding a pooled estimate of 6.43 (3.57-11.56 ) events per million doses was not importantly different in terms of rarity, (3) that this study was balanced by other studies with 0 events, and (4) visual inspection did not reveal serious inconsistency. c. Values in parentheses are data restricted to studies with 20,000 or more doses. Explanations a. These were all case reports, with non-random selection of cases and controls b. Challenges to the agents were not performed to confirm accuracy of the testing c. Different agents and methods were used for testing and reported positives from these test d. Low numbers of cases were tested to derive these estimates. Bias is suspected as authors are more likely to report severe cases or cases with positive testing, whereas milder cases or cases with negative testing may not be report Recommendation 2: For patients with no history of a previous allergic reaction to a SARS-CoV-2 vaccine or its excipients the requirement for additional observation beyond standard wait time (e.g., recommended by local health authorities for the general population) provides a minimal absolute risk reduction in severe anaphylaxis outcomes and may also contribute to vaccine hesitancy. Therefore, we suggest against prolonged observation in those with a history of anaphylaxis unrelated to a SARS-CoV-2 vaccine or excipient. Conditional Recommendation; Low Certainty of Evidence 90.7% Mean score: 4.53 This may provide some patients with peace of mind and reassurance; I admit this is more art than science, but would not favor this recommendation, although qualified as conditional. When I have done this for selected patients (e.g., someone with venom anaphylaxis, not a patient with pollen-fruit syndrome) they do not view this as a burden, but seem to welcome the recommendation to prolong the wait time to 30 minutes; strongly agree; Is there evidence that longer wait contributes to vaccine hesitancy; Consider deleting word "also" so it reads "provides a minimal absolute risk reduction in severe anaphylaxis outcomes and may contribute to vaccine hesitancy""; The words "no history of anaphylaxis" in Question 1 could be replaced by "no history of allergic reactions" to be consistent with what reported in both Recommendation 1 and 2; They are not at increased risk; I have had patients who will only get the vaccine because they can wait and others ask if they really have to stay; If it makes some patients safer to receive the vaccine this way, it can be recommended to increase vaccine compliance (i.e. SDM) Recommendation 3: In patients with no history of anaphylaxis to SARS-CoV-2 vaccines or its excipients, we suggest against vaccine or vaccine excipient testing prior to vaccination prior to vaccination in an attempt to predict the rare individual who will have a severe allergic reaction to vaccination.. Strong recommendation; Low Certainty of Evidence.

Mean score: 4.82 There are patients who have had anaphylaxis to a chemotherapeutic agent who I would judge as meriting skin testing --are they included in this statement?; strongly agree; Please note that in Table 4 , the description of the Jonhson and Jonhson vaccine seems to be missing; For table 4, I do not recall seeing the Johnson and Johnson vaccine listed but maybe I missed it. For figure 2, would it be clearer to say incidence per ten thousand "reports" on the x axis? Otherwise, it may seem like there are a lot more people with PEG allergy? Recommendation 4: We suggest against the clinician routinely performing skin or in vitro testing using SARS-COV-2 vaccines or excipients outside of the research setting for the purposes of vaccine withholding, given such testing has unknown sensitivity/specificity in predicting severe allergic reactions, including anaphylaxis, to SARS-CoV-2 vaccines. Conditional recommendation; Low Certainty of Evidence 88.9% Mean score: 4.51

The key word here is "routinely"; strongly agree; What is clear based on the literature is that anaphylaxis with confirmed sensitization to PEG is possible, can be demonstrated by skin testing and serum IgE. Just because PEG allergy is a relatively rare event, does not mean there is no value in doing testing if it can be done. It is hard to establish testing validity for rare events and apply it to more widely--unless testing on those who have had anaphylaxis were to actually be done on a wider level (which would help establish its validity). This data should be collected as part of a research protocol, which isn't the same as saying don't do it at all.?; Given that Recommendation 4 is "conditional with low certainty of evidence" and that (line 473-474) "there is no elaboration on how the allergy specialist should evaluate these patients to determine whether vaccination is advisable and how to proceed" and that (Line 392-393) "testing may be considered as a preference sensitive option.." Figure 3 should report this option somewhere either in the box on the right or in the footnote (something like Can consider skin testing to vaccine or excipient(s) however, predictive value of this testing is not known and is recommended to be limited to research contexts). Please note that in Table 2 there is a mistake as the Recommendation Strength is reported as "Strong" while in the main manuscript is reported as "Conditional"; This statement is too strong in my view. In many countries and clinical settings this recommendation is hard to implement. It is fairly mentioned in the manuscript that ASCIA and WAO consider skin testing to the vaccine or its components an option. In the light of available evidence my suggestion would be to change the statement to "we cannot suggest for or against..." There is a sentence in the manuscript "While testing may be considered as a preference-sensitive option in shared decision-making, options for cautious administration of vaccine (Figure 3 ) or the use of an alternative vaccine with a different platform and excipient may be more practical choices" which also somehow contradicts recommendation in its' current form. ASCIA and WAO; NB: Table 2 has "strong" recommendation; in specialized units this may be performed even though there is no formal research project and may add to knowledge; For figure 3, it seems like boxes 1 and 2 only differ by 15 minute wait so risk of SARS-COV-2 are essentially the same. Should we add lack of availability of vaccines to specialist offices in this figure?; "Routinely" makes this question a "1" but feel this should be discussed, along with limits of sensitivity/specificity, with patient and some may wish to have testing. Routinely the answer is clearly a 1. Recommendation 5: We recommend a shared decision-making paradigm of care favoring vaccination through full or graded dosing (with or without additional observation time post-vaccination) or changing vaccine platforms to another agent over no vaccination because there is no single best approach to assessment and management of the patient with a suspected SARS-CoV-2 mRNA or adenovirus vector vaccine reaction, or the patient with an allergy to an excipient 96.3% Mean score: 4.71 I'm on the fence with this one based on wording. Not sure whether we're talking about anaphylaxis when you say "generalized systemic allergic reaction"; I've had patients with urticaria who have gone on to receive round 2 with pretty much the same (and not more serious) reaction. Also, the statement states "suspected" vaccine reaction rather than actual reaction. Let me know if you wanna discuss this further; strongly agree; Figure 3 : I would keep the red/green colors only in the 2 arrows, because the different colors in the 4 graphs create confusion and make it difficult to read the lines. Also in the last graph it is stated "Unclear protective efficacy of a single dose". It should J o u r n a l P r e -p r o o f 4 in either of these vaccines who has not yet been vaccinated. Strong Recommendation; Moderate Certainty of Evidence be specified that this refers to the 2 doses vaccine and not the single dose (eg. Jonhson and Jonhson); For table 5, if we are using shared decision making, how can you blind a placebo dose for someone with anxiety?; Statement is too vague; For those with previous reactions to excipients, physicians should see if these excipients were tolerated in other vaccines or medicine too; Many physicians want a straightforward, "cookbook" answer and flow diagram on what to do with vaccine reactions. It is emphasized very well that individual physician judgment is essential and vital. Recommendation 6: In patients with suspected immediate allergic reaction to SARS-CoV-2 vaccine whose standard schedule requires more than one dose, we recommend referral to an allergist for assessment of additional vaccination over no/deferred vaccination Strong Recommendation; Moderate Certainty of Evidence 98.1% Mean score: 4.82 Strongly agree; In my opinion the recommendation as currently stated allows for wide interpretation in terms of the type of patient that is appropriate for referral to an allergist; Recommendation 6 and 8 seems very similar with regards to allergic reaction to SARS-COV2 vaccine; We allergists/immunologists are indeed the experts.

In patients with a suspected or confirmed but remote history of reaction to a vaccine excipient, we recommend referral to an allergist for assessment of additional vaccination over no vaccination/vaccination being withheld. In resource limited settings where specialist referral is not readily available, alternatives may be presented in a shared decision-making context to provide assessment and opportunity for vaccination by remote consultation, use of alternative vaccine products, or delay in vaccination until a solution can be determined. Strong Recommendation; Moderate Certainty of Evidence 98.1% Mean score: 4.78 Strongly agree; What do you mean by remote? Do you mean a non-local reaction? If so, suggest wording is changed to "with a suspected or confirmed systemic reaction to a vaccine excipient"; In my opinion the recommendation as currently stated allows for wide interpretation in terms of the type of patient that is appropriate for referral to an allergist; My only concern is that many allergists really may not know what to do; Strongly agree with statement but we options for the specialist are limited other than a shared-decision making discussion. This is particularly a problem if the specialist does not have access to the vaccine.

Recommendation 8: In patients with a definite/confirmed recent allergic reaction to SARS-CoV-2 vaccine and/or excipient, we recommend referral to an allergist for assessment of additional vaccination over no vaccination/vaccination being withheld. In resource limited settings where specialist referral is not readily available, alternatives may be presented in a shared decision-making context to provide assessment and opportunity for vaccination by remote consultation, use of alternative vaccine products, or delay in vaccination until a solution can be determined. Strong Recommendation; Low Certainty of Evidence 98.1% Mean score: 4.82 Strongly agree; Despite the clarified definition of allergic reaction as generalized and systemic I still believe that that the recommendation is open to wide interpretation. I thought the phrase used in earlier version was more appropriate : ": We recommend that an allergist-immunologist evaluation be considered as a possible path in support of such patients being vaccinated,"; the strong likelihood here is that no further vaccine will be given Recommendation 9: While all vaccines should be administered in facilities capable of treating anaphylaxis, particularly for individuals with a prior immediate systemic allergic reaction to a SARS-CoV-2 vaccine or vaccine excipient, we recommend the clinician should administer SARS-CoV-2 mRNA or adenovirus vector vaccine in a setting equipped to manage anaphylaxis (e.g. hospital, mass immunization clinic, specialist office), under the supervision of personnel trained in the recognition and management of anaphylaxis. In resource limited settings where specialist referral is not readily available, alternatives may be presented in a shared decision-making context to provide assessment and opportunity for vaccination by remote consultation, use of alternative vaccine products, or delay in vaccination until a solution can be determined. Strong Recommendation; Moderate Certainty of Evidence 94.4% Mean score: 4.80 Patients who are candidates for the vaccine can be stratified such that higher risk patients observe this recommendation. For individuals in the gen'l population without risk factor(s), this is not necessary and would interfere with efforts to vaccinate rapidly to achieve herd immunity; If this is routine vaccination, this is not needed as we state the risk is so low. Probably need to reword if this in regards to prior vaccine reactors; strongly agree; should make the wording clearer to explain this is just for those with definite or confirmed reactions; I am not sure about the e.g. specialist part since most Covid vaccines are not given by specialists and most allergists I know cannot obtain vaccine for their offices. If we want to emphasize the specialist, we may need to emphasize making vaccine available to allergy specialist offices (maybe add somewhere in lines 501-512); Routine vaccination should not require a specialist but the staff should be equipped to treat reactions. The "e.g." confused me as to the intent of question; Only in those with a history of anaphylaxis Recommendation 10: We suggest against routine H1-antihistamine or systemic corticosteroid pre-medication prior to vaccination as it has low certainty evidence in preventing anaphylaxis, and theoretically corticosteroid premedication could diminish the immune response. Conditional Recommendation; Low Certainty of Evidence 98.1% Mean score: 4.75 I believe this is more than "theoretical"; strongly agree; What saves this statement is the use of the word "routine".

In the text can state if a high risk person needs vaccine and has reacted to first dose, this is sdm based on precedent for prevention of complement mediated reactions. As much evidence for this as graded challenges to vaccines being recommended; We studied this for DT vaccine years ago, some effect on primary, no significant effect of OCS on booster; one could argue H1 antihistamine is a VERY low risk med to use. Would have considered changing to strong rec against for steroids only; this leaves latitude to pretreat with an H1 antihistamine in anxious patients; True with regard to anaphylaxis, but may have value in decreasing local and non-anaphylactic reactions/side effects. Recommendation 11: We recommend in favor of globally coordinated research studies being conducted to address i) vaccine and vaccine excipient testing diagnostic accuracy for allergy to SARS-CoV-2 vaccines; ii) administration of the vaccine to individuals with prior anaphylaxis to the vaccine or vaccine excipient; iii) the necessity of graded vaccine administration in the context of a patient with possible SARS-CoV-2 vaccine allergy; iv) the safety, efficacy, and necessity of mixing SARS-CoV-2 vaccine platforms; and v) the incremental benefit of additional doses of an mRNA or certain adenovirus-vector vaccines 100% Mean score: 4.96

Great job with this!!!; strongly agree; Line 342 in manuscript should be sensitivity not specificity. Recommendations 4 and 10 need some more elaboration in the text of the document; Good to work towards these studies; Outstanding, clinically relevant points.

J o u r n a l P r e -p r o o f This table demonstrates the anaphylaxis risk threshold projected using different modeled scenarios considering efficacy of the first dose and increase in second dose protection against symptomatic COVID-19 infection. The degree to which first and second dose offer protection to others was not specifically modelled and could increase the anaphylaxis threshold at which second dose deferral would be cost-effective. *Evaluation of cost-effectiveness threshold (willingness to pay: $10,000,000 per death prevented) of anaphylaxis risk for a second dose of an mRNA SARS-CoV-2 vaccination from a societal perspective. Anaphylaxis risk threshold represents the value at which second vaccine deferral is cost-effective in an at-risk population who has received some degree of durable protection from a first vaccination for the ensuing 12 months. J o u r n a l P r e -p r o o f Question 4: Should SARS-CoV-2 mRNA or adenovirus vector vaccines be administered to an individual who had an immediate allergic reaction to the first dose of the vaccine (defined as a generalized, systemic allergic reaction with acute onset occurring within 4 hours of vaccine administration), or given as a first dose to an individual who is suspected to have reacted previously to an excipient ingredient that is also present in the SARS-CoV-2 mRNA or adenovirus vector vaccines?

Data extraction Data extraction will occur independently and in duplicate. Any disagreement will be resolved by discussion, and if needed, a third author. We will extract, apart from the outcome measures, study characteristics including Author, year, country (ies), study design, definition of anaphylaxis (including adjudicated versus not).

Risk of bias assessment will use done per question using the most appropriate tool. For questions 1 and 2 addressing risk, we will use the JBI risk of bias tool for prevalence studies. For the diagnostic test accuracy question, we will use QUADAS-2.

Given that we anticipate the events to be rare and of risks, we will meta-analyze proportions by logistic-normal random effects. Statistical heterogeneity will be assessed using the GRADE approach, as I 2 will likely be misleading in pooling large observational studies. Given the likelihood for sparse data for diagnostic test accuracy with zeros in the more than one cell of the 2x2 table, we anticipate specificity to be falsely high, and will report raw pooled sensitivity specificity across trials. Supplemental analyses may use a Bayesian approach. Analysis will be done using Stata 14.3. We will use the GRADE approach (GRADE Working Group. GRADE home. Available from: http://www.gradeworkinggroup.org) will be used for rating the overall quality of evidence.

1. Anaphylaxis to be higher among studies with no clear adjudication of anaphylaxis, as there are many mimickers of anaphylaxis. 2. mRNA vaccines are more likely than other types of vaccines to cause anaphylaxis.

All subgroup analyses will employ tests for interaction.

Intervention, Meta-analysis, Systematic review 

Five reviewers screened records independently and in duplicate using Covidence, for initial inclusion, full text inclusion, and final inclusion for data extraction. A total of two reviewers were minimally required to render a decision for any abstract, and a threshold of 2 votes to include or exclude a particular abstract was used. Conflicts were resolved by direct discussion between the conflicting reviewers. Search terms were generated by DC, AB, and AWB. Inclusion criteria included human studies only, clinical studies of >20,000 patients for reporting allergic reactions to SARS-CoV-2 or vaccination data from country specific datasets reporting >500,000 vaccines, for any type of SARS-CoV-2 vaccine platform (question 1); clinical studies or data reporting sources detailing a patient or physician reported national level dataset for drug allergy to PEG of any molecular weight and in any form or any form of polysorbate (question 2); and any study or case series reporting skin testing (prick, percutaneous, and/or intradermal testing) to any molecular weight and concentration of PEG or polysorbate in which negative controls were also tested, and where true/false negatives as well as true/false positives were reported, inclusive of any testing threshold to denote sensitization. Exclusion criteria for question 1 included reports/studies smaller than the pre-specified threshold; for question 2 included case reports or case series not derived from large, centralized data collection systems or from single centers; and for question 3 included studies and series that did not report negative control subjects were also tested, did not report the size of the test, that described atopy patch testing for contact dermatitis, or that related to testing of a reaction to PEGalated chemotherapy where it was not distinctly clear that the PEG or the chemotherapy were the provoking agent.

We searched the global coronavirus database: ((tw:(allerg*)) OR (tw:(anaphyl*))) AND (tw:(vaccin*))

We evaluated all studies mapped as of March 19, 201 : https://covid-nma.com/vaccines/ We searched for "[country name] vaccine adverse event", "[country name] vaccine allergy" , and "[country name] vaccine anaphylaxis" for all countries reporting more than 500,000 vaccinations according to OurWorldInData as of March 19, 2021 2) Question 2: Prevalence of allergic reactions to PEG and Polysorbate Legend: Panel A: Two-way sensitivity analysis of anaphylaxis risk and COVID-19 risk. As risk of COVID-19 increased, cost-effectiveness of a risk-stratified required vaccine deferral at higher anaphylaxis risk thresholds. Red area shows where universal vaccination is the optimal strategy, and blue area shows where risk stratification is the optimal strategy. Panel B: Two-way sensitivity analysis of risk-stratification by time. Evaluating risk stratification of anaphylaxis risk by observation time, a universal approach of 15 minute observation was preferred until risk of anaphylaxis and anaphylaxis case-fatality rates rose significantly (red area). However, if a 1% anaphylaxis case-fatality was assumed, a risk-stratified approach of 30 minute (vs 15 minute) observation became cost-effective when vaccine anaphylaxis exceeded 6% (WTP = 10,000,000 per death prevented) (blue area)

COVID-19-New Insights on a Rapidly Changing Epidemic

Global Preparedness Monitoring Board. A World in Disorder. Global Preparedness 1242 Monitoring Board Annual Report 2020. Geneva: World Health Organization

Dzharullaeva 1250 AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-1251 boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies 1252 from Russia

SARS-CoV-2 vaccines in 1254 advanced clinical trials: Where do we stand?

Vaccines and Related Biological Products Advisory Committee Meeting

Vaccines and Related Biological Products Advisory Committee Meeting

Dzharullaeva 1262 AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost 1263 COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Covid-19: People with history of significant allergic reactions should not 1269 receive Pfizer vaccine, says regulator

mRNA Vaccines 1271 to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested 1272 Approach

Immediate 1276 Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have 1277 Recognized

Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested 1282 Approach

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna 1293 COVID-19 Vaccine -United States

Team CC-R, Food, Drug A. Allergic Reactions Including Anaphylaxis After Receipt of the 1296 First Dose of Moderna COVID-19 Vaccine -United States

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of 1300 immunization safety data

AGREE II: 1308 advancing guideline development, reporting and evaluation in health care

Grading quality of 1315 evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The 1316 GRADE approach to grading quality of evidence about diagnostic tests and strategies

Grading quality of 1319 evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The 1320 GRADE approach to developing recommendations

Safety and 1366 immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-1367 blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, 1368 randomised phase 1 trial

Safety and 1376 immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: 1377 interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study

CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Efficacy of the 1382 ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

An in-depth investigation of the safety and 1390 immunogenicity of an inactivated SARS-CoV-2 vaccine

Safety and 1392 immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in 1393 healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Interim 1396 Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Preliminary Efficacy 1398 of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Safety and 1401 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of 1402 four randomised controlled trials in Brazil, South Africa, and the UK

Phase 1 trial of a 1407 Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

Safety, tolerability, and immunogenicity 1413 of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a 1414 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Effect of an Inactivated Vaccine 1416 Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 1417 Randomized Clinical Trials

Safety and immunogenicity of an 1419 inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, 1420 phase 1/2 trial

Safety and immunogenicity of a recombinant 1422 tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two 1423 randomized, double-blind, placebo-controlled, phase 1 and 2 trials

Immunogenicity and safety of a 1429 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or 1430 older: a randomised, double-blind, placebo-controlled, phase 2 trial

International Consensus (ICON): allergic reactions to vaccines

Adverse events associated with childhood vaccines: 1434 evidence bearing on causality

Anaphylaxis after vaccination 1436 reported to the Vaccine Adverse Event Reporting System

Antibiotic allergy

Fatal Anaphylaxis: 1441 Mortality Rate and Risk Factors

Primary care reported 1443 prevalence of vaccine and polyethylene-glycol allergy in Canada

Second symposium on the definition and management of anaphylaxis: summary report--Second 1449 National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 1450 symposium

World allergy organization anaphylaxis guidance 2020

Time to revisit 1456 the definition and clinical criteria for anaphylaxis?

Anaphylaxis Safety Data of COVID-19 Vaccines

Diagnostic utility of two case definitions for anaphylaxis: a comparison using a retrospective 1462 case notes analysis in the UK

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost 1465 regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 1466 trial

Vaccine Task Force: Allergic 1471 Reactions to mRNA SARS-CoV-2 Vaccines

Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies

The 1478 Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the 1479 Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis

Interim 1482 Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in 1483 Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other 1484 Essential and Frontline Workers -Eight

Adverse 1490 reactions to vaccines practice parameter 2012 update

Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic 1493 Patients

Polyethylene Glycol-Induced Systemic Allergic Reactions 1495 (Anaphylaxis)

Allergy to macrogols: A case report

Hypersensitivity to polyethylene glycols

Macrogol 1505 hypersensitivity reactions during cleansing preparation for colon endoscopy

Anaphylaxis due to polyethylene glycol: A case report

Usefulness of oral macrogol challenge in anaphylaxis 1510 after intra-articular injection of corticosteroid preparation

Anaphylaxis due to macrogol in a laxative solution with a positive basophil 1513 activation test

Two cases of anaphylaxis to 1517 macrogol 6000 after ingestion of drug tablets

Immediate hypersensitivity to polyethylene glycols in unrelated products: when 1520 standardization in the nomenclature of the components of drugs, cosmetics, and food becomes 1521 necessary

Immediate allergic 1523 reactions by polyethylene glycol 4000: two cases

Multiple Drug Allergy Due to Hypersensitivity to 1526

Polyethylene Glycols of Various Molecular Weights

Biologic-induced urticaria due to 1529 polysorbate 80: usefulness of prick test

High volume of polysorbate-containing (Tween((R)) 80) solutions 1531 induces false-positive results in intradermal test

Hypersensitivity reaction to human papillomavirus 1533 vaccine due to polysorbate 80

Polysorbate 80 hypersensitivity

Polysorbate 80 in medical products and 1537 nonimmunologic anaphylactoid reactions

An allergic reaction to erythropoietin secondary 1539 to polysorbate hypersensitivity

Polyethylene Glycol and Polysorbate 1541

Epub ahead of print. . 1544 118. Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines

Administration of a Second Dose of the Moderna 1551 COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case 1552 Reports

Allergy to 1556 Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient 1557 and the Management of Future Exposure to SARS-CoV2. Vaccines (Basel) 2021;9. 1558 123. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines

Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General 1562 Population

Anti-PEG IgE in 1564 anaphylaxis associated with polyethylene glycol

Pegaspargase Allergic Reactions and Failure of Rechallenge

Animal models of 1568 complement-mediated hypersensitivity reactions to liposomes and other lipid-based 1569 nanoparticles

Allergenic components of 1571 the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-1572 mediated complement activation

Anaphylaxis to 1574 trometamol excipient in gadolinium-based contrast agents for clinical imaging

Activation of mast cells by double-1579 stranded RNA: evidence for activation through Toll-like receptor 3

Allergic 1584 symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE

Administration of influenza vaccines to egg allergic 1587 recipients: A practice parameter update 2017

Safe vaccination 1589 of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine

Case fatality and population mortality associated with 1592 anaphylaxis in the United States

Keirns CC, Goold SD. Patient-centered care and preference-sensitive decision making

ARIA-EAACI 1608 statement on severe allergic reactions to COVID-19 vaccines -an EAACI-ARIA

Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of 1615 Recommendations, Assessment, Development and Evaluation (GRADE) analysis

Initial real world 1621 evidence for lower viral load of individuals who have been vaccinated by BNT162b2

Early rate reductions of SARS-CoV-2 1624 infection and COVID-19 in BNT162b2 vaccine recipients

Golden: development of the literature search questions, literature search, abstract review and data abstraction, data analysis

Brown: development of the literature search terms, literature search, abstract review and data abstraction

Dribin: conducting of the Delphi panel, iterative critical review of the manuscript John Witty: conducting of the Delphi panel Cem Akin

CoV-2 vaccine reaction or vaccine excipient allergy seeking vaccination (questions 1 and 2) and patients with known (or suspected) SARS-CoV-2 vaccine reaction or vaccine excipient allergy seeking vaccination (question 3). The questions developed included the following: Question 1: What is the risk of a severe allergic reaction, including anaphylaxis, to a SARS-CoV-2 vaccine in a patient with no history of a severe allergic reaction to a SARS-CoV-2 vaccine or its excipients? Population: Patients without known SARS-CoV-2 vaccine reaction or vaccine excipient allergy seeking vaccination Intervention: SARS-CoV-2 vaccination Comparator: Defer SARS-CoV-2 vaccination Outcome: Allergic reaction to a SARS-CoV-2 vaccine Question 2: In patients without a history of a severe allergic reaction, including anaphylaxis, to a SARS-CoV-2 vaccine or its excipients, should allergy skin testing to SARS-CoV-2 vaccines or its excipients be performed? Population: Patients without known SARS-CoV-2 vaccine reaction or vaccine excipient allergy seeking vaccination Intervention: Allergy skin testing to SARS-CoV-2 vaccines or its excipients (PEG, polysorbate 80) Comparator: Not performing allergy skin testing to SARS-CoV-2 vaccines or its excipients (PEG, polysorbate 80) Outcome: Allergic reaction to a SARS-CoV-2 vaccine Question 3: In patients with a history of a severe allergic reaction, including anaphylaxis, to a SARS-CoV-2 vaccine or its excipients, should allergy skin testing to SARS-CoV-2 vaccines or its excipients be performed to determine if vaccine withholding is needed? Population: Patients with a known SARS-CoV-2 vaccine reaction or vaccine excipient allergy seeking vaccination Intervention: Allergy skin testing to SARS-CoV-2 vaccines or its excipients (PEG, polysorbate 80) Comparator: Not performing allergy skin testing to SARS-CoV-2 vaccines or its excipients (PEG, polysorbate 80) Outcome: Allergic reaction to a SARS-CoV-2 vaccine Search

14044) 2 exp macrogol/ or exp macrogol 10000

1817668) 7 diagnostic accuracy.sh. (262948) 8 diagnostic.tw. (1044645) 8 (2786336) 10 exp allergy/ or allerg*.mp. (379550) 11 exp hypersensitivity/ or hypersens*.mp. (668129) 12 exp anaphylaxis/ or anaphyla*.mp. (67077) 9 and 13 (299) 15 from 14 keep 1-299 (299) 16 prevalence.mp

Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Search Strategy

Sensitivity and Specificity"/ (601394)

polyethylene glycol (PEG) and/or polysorbate(s)

Diagnostic testing precision for allergy testing to PEG and Polysorbate J o u r n a l P r e -p r o o f We searched MEDLINE and EMBASE and used all databases in Web of Science forward and backward citation analysis: C1 -Database: Ovid MEDLINE(R) ALL <1946 to March 18

Sensitivity and Specificity"/ (601394)

Embase <1974 to 2021 March 18> Search

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US

Acute Allergic Reactions to mRNA COVID-19 Vaccines

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study

Efficacy of the ChAdOx1 nCoV

Covid-19 Vaccine against the B.1.351 Variant

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2

Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Phase 1-2 Trial of a SARS

Recombinant Spike Protein Nanoparticle Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, doubleblind, placebo-controlled trial

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized

Primary care reported prevalence of vaccine and polyethylene-glycol allergy in Canada

Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis)

Immediate-type hypersensitivity to polyethylene glycols: a review

Allergy to macrogols: A case report

Hypersensitivity to polyethylene glycols

Macrogol hypersensitivity reactions during cleansing preparation for colon endoscopy

Anaphylaxis due to polyethylene glycol: A case report

Usefulness of oral macrogol challenge in anaphylaxis after intra-articular injection of corticosteroid preparation

Anaphylaxis due to macrogol in a laxative solution with a positive basophil activation test

Macrogol hypersensitivity in multiple drug allergy

Two cases of anaphylaxis to macrogol 6000 after ingestion of drug tablets

Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary

Immediate allergic reactions by polyethylene glycol 4000: two cases

Multiple Drug Allergy Due to Hypersensitivity to Polyethylene Glycols of Various Molecular Weights

Biologic-induced urticaria due to polysorbate 80: usefulness of prick test

High volume of polysorbate-containing (Tween((R)) 80) solutions induces falsepositive results in intradermal test

Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80

Polysorbate 80 hypersensitivity

Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions

An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity

Based on n=54 votes and 2 rounds of voting. Of 63 total authors, 3 did not vote due to strictly methodological roles, and 2 voted in the first round but not the 2 nd as their IT systems repeatedly blocked the voting email. Four authors were added right as the second round of voting started, and these individuals were asked to rate their agreement outside of the voting, given we had already reached agreement threshold on the first vote (the second vote was to affirm minor wording changes) and worst-case scenario sensitivity analysis of these 6 authors noted no effect on reaching the agreement threshold (>75% voting "agree" [4] or avove). Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) AND AT LEAST ONE OF THE FOLLOWING a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia) b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia (collapse], syncope, incontinence) 2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours): a. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lipstongue-uvula) b. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia) c. Reduced BP or associated symptoms (eg, hypotonia [collapse] , syncope, incontinence) d. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting) 3. Reduced blood pressure after exposure to known allergen for that patient (minutes to several hours): a. Infants and children: low systolic BP (age specific) or greater than 30% decrease in systolic BP b. Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that person's baseline Anaphylaxis is highly likely when any one of the following 2 criteria are fulfilled:1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g. generalized hives, pruritus or flushing, swollen lips-tongue-uvula) AND AT LEAST ONE OF THE FOLLOWING: a. Respiratory compromise (e.g. dyspnea, wheezebronchospasm, stridor, reduced PEF, hypoxemia) b. Reduced BP or associated symptoms of end-organ dysfunction (e.g. hypotonia [collapse], syncope, incontinence) c. Severe gastrointestinal symptoms (e.g. severe crampy abdominal pain, repetitive vomiting), especially after exposure to non-food allergens 2. Acute onset of hypotension* or bronchospasm or laryngeal involvement after exposure to a known or highly probable allergen for that patient (minutes to several hours), even in the absence of typical skin involvement.*Criteria are co-endorsed by 50 global allergy societies, but not AAAAI or EAACI